Nate is a Senior Analyst on Samsara BioCapital’s investment team. He joined the fund in September 2020. Prior to Samsara, Nate spent two years on an Institutional Investor-ranked biotechnology equity research team at Stifel Nicolaus & Co. focusing on CNS and rare disease therapeutics. At Stifel, Nate served as lead associate and was responsible for conducting clinical, commercial, and financial diligence and creating deep dive-oriented investment research. Previously, Nate was a senior associate on a sell- side equity research team at Stephens Inc. where he covered ~60 companies across the financial sector, specializing in mid and large-cap depository institutions.
Nate received a B.A. in Economics from Bates College and is a CFA Level II Candidate.